Pfizer Inc. expanded its highly automated Active Pharmaceutical Ingredient (API) manufacturing facility located in Tuas Biomedical Park, Singapore. The cutting-edge facility extension, valued at SGD$1 billion, will manufacture various small molecule APIs for Pfizer’s oncology, pain, and antibiotic medications for global markets. The facility has completed all required final performance qualification checks and has commenced commercial production.
The construction of the facility began in 2020, emphasizing efficient material movement, reduced lead times, quick process turnarounds, and adherence to Good Manufacturing Practices (GMP). In addition to the existing structures, the facility is equipped to add processing suites, dry-end suites, dispensaries, warehouses, and ancillary equipment as needed.
The design also prioritizes the integration of systems and technologies to enhance energy efficiency and enable effective energy demand management. The facility has earned a Green Mark Gold certification, a Singapore accreditation for environmental sustainability. As reported by biopharmaapac.com, the efforts align with Pfizer’s objective to achieve the voluntary Net-Zero standard by 2040, contributing to a sustainable future.
